Home - TG Therapeutics
WEBlatest news New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92
WEB4 days ago · NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated data presentations including new five-year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and ...
TG Therapeutics Reports BRIUMVI Data From ENHANCE Phase 3b …
WEB4 days ago · Sep. 18, 2024, 08:24 AM. (RTTNews) - TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The ...
TG Therapeutics Stock Surges After Preventing MS Relapses Over …
WEB4 days ago · Related news TG Therapeutics Receives Composite Rating Upgrade. 9/09/2024 TG Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Tuesday, from 94 to 97.
TG Therapeutics - New BRIUMVI Data from the ENHANCE Phase …
WEB3 days ago · NEW YORK - TG Therapeutics, Inc. (NASDAQ: TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated ...
TG Therapeutics Reports BRIUMVI Data From ENHANCE Phase 3b …
WEB4 days ago · TG Therapeutics presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis.The company said the data showed rapid 30 minute infusions were well tolerated. Data also showed that patients switching from prior anti-CD20 treatment …
TG Therapeutics Announces FDA Approval of BRIUMVI™ …
WEBNEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the U.S. Food and Drug Administration (FDA) has approved BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and …
Are Robust Financials Driving The Recent Rally In TG Therapeutics…
WEB3 days ago · So, based on the above formula, the ROE for TG Therapeutics is: 54% = US$96m ÷ US$178m (Based on the trailing twelve months to June 2024). The 'return' is the yearly profit.
TG Therapeutics, Inc. (TGTX) Latest Stock News & Headlines
WEBGet the latest TG Therapeutics, Inc. (TGTX) stock news and headlines to help you in your trading and investing decisions.
TG Therapeutics Announces Global License Agreement with
WEBNEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), “the Company,” today announced that it has entered into an agreement with Precision BioSciences, Inc. (NASDAQ...
Skip to content